Skip to main content

Table 2 Regression results for costs and reimbursements

From: In-hospital costs of community-acquired colonization with multidrug-resistant organisms at a German teaching hospital

 

(1)

(2)

(3)

(4)

Costs

Costs

Reimbursements

Reimbursements

Community-onset cases

0.256***

 

0.158***

 

[0.224,0.289]

 

[0.129,0.188]

 

Marginal effect in €

1480.9***

 

887.8***

 

[1286.4,1675.5]

 

[722.1,1053.6]

 

MRSA

 

0.286***

 

0.212***

 

[0.222,0.350]

 

[0.154,0.270]

Marginal effect in €

 

1651.3***

 

1188.6***

 

[1279.1,2023.6]

 

[861.1,1516.1]

VRE

 

0.152***

 

0.0583***

 

[0.105,0.200]

 

[0.0162,0.100]

Marginal effect in €

 

879.2***

 

326.5***

 

[604.1,1154.2]

 

[90.52,562.5]

MDR-GN

 

0.341***

 

0.236***

 

[0.284,0.397]

 

[0.186,0.286]

Marginal effect in €

 

1966.0***

 

1320.9***

 

[1634.6,2297.4]

 

[1038.3,1603.4]

CCI

0.0533***

0.0541***

0.0433***

0.0440***

[0.0469,0.0597]

[0.0477,0.0605]

[0.0377,0.0489]

[0.0384,0.0496]

N

9923

9923

9923

9923

  1. Note: All Models are estimated with GLM regressions. Coefficients are exponentiated and substracted by 1. All columns include within main diagnosis fixed effect and are controlled for age, age2 and sex. CCI: Charlson comorbidity index. 95% confidence intervals in brackets
  2. *p < 0.1, **p < 0.05, ***p < 0.01